SCHEMBL21481971

SCHEMBL21481971

COc1ccc2cc(-c3ccc(Cn4ncc5c(Cl)ccc(C(=O)NC6CCC(CC(=O)O)CC6)c54)cc3)ccc2n1

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 8/20 0.40
CNR2 P34972 7/20 0.37
CNR1 P21554 2/20 0.37
KLK7 P49862 1/20 0.35
HPGDS O60760 1/20 0.34
DGAT1 O75907 1/20 0.34
CHRM4 P08173 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22927026 0.92 CNR2 (0.39) CRHR1CNR2CNR1KLK7HPGDS
SCHEMBL21481972 0.91 CNR2 (0.33) CRHR1CNR2CNR1HPGDSCHRM4
SCHEMBL21458303 0.91 CNR2 (0.33) CRHR1CNR2CNR1HPGDSCHRM4
SCHEMBL30843277 0.91 CNR2 (0.33) CRHR1CNR2CNR1HPGDSCHRM4
SCHEMBL21481940 0.88 CRHR1 (0.37) CRHR1CNR2CNR1KLK7HPGDS
SCHEMBL21485595 0.86 NTRK1 (0.39) CRHR1CNR2CNR1KLK7
SCHEMBL24992167 0.85 CRHR1 (0.39) CRHR1CNR2CNR1HPGDSCHRM4
SCHEMBL22927027 0.84 CNR2 (0.35) CNR2CNR1HPGDS
SCHEMBL21481881 0.84 CRHR1 (0.42) CRHR1CNR2CNR1
SCHEMBL21481869 0.84 CRHR1 (0.42) CRHR1CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CRHR1 87/4885CNR2 3/4885CNR1 6/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CRHR1 87/4885CNR2 3/4885CNR1 6/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CRHR1 87/4885CNR2 3/4885CNR1 6/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CRHR1 87/4885CNR2 3/4885CNR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.